



## Preauthorization Statistics for Arkansas Plans with Wellfleet Rx/ESI

### Q4 2023

No Preauthorization Requests for Arkansas plans during Q4 2023 (10/1/23-12/31/23)

### Q3 2023

<b>Provider Specialty Type</b>	<b>Drug</b>	<b>Treatment Description</b>	<b>Decision</b>
FAMILY MEDICINE	Myrbetriq 25mg ER tab	Overactive Bladder	Denied
PODIATRY	Hydrocodone/APAP 5mg/325mg tab	Moderate to Severe pain	Approved

### Q2 2023

No Preauthorization Requests for Arkansas plans during Q2 2023 (4/1/23-6/30/23)

### Q1 2023

No Preauthorization Requests for Arkansas plans during Q1 2023 (1/1/23-3/31/23)

### Q4 2022

No Preauthorization Requests for Arkansas plans during Q4 2022 (10/1/22-12/31/22)

### Q3 2022

<b>Provider Specialty Type</b>	<b>Drug</b>	<b>Treatment Description</b>	<b>Decision</b>
INTERNAL MEDICINE	Winlevi 1% cream	Acne Vulgaris	Denied

### Q2 2022

No Preauthorization Requests for Arkansas plans during Q2 2022 (4/1/22-6/30/22)

### Q1 2022

No Preauthorization Requests for Arkansas plans during Q1 2022 (1/1/22-3/31/22)



**Q4 2021**

<b>Provider Specialty Type</b>	<b>Drug</b>	<b>Treatment Description</b>	<b>Decision</b>
INTERNAL MEDICINE	Promacta 75mg Tablet	Immune thrombocytopenic purpura	Approval

**Q3 2021**

<b>Provider Specialty Type</b>	<b>Drug</b>	<b>Treatment Description</b>	<b>Decision</b>
INTERNAL MEDICINE	Promacta 75mg Tablet	Immune thrombocytopenic purpura	Approval

**Q2 2021**

No Preauthorization Requests for Arkansas plans during Q2 2021 (4/1/21-6/30/21)

**Q1 2021**

No Preauthorization Requests for Arkansas plans during Q1 2021 (1/1/21-3/31/21)

**Q4 2020**

No Preauthorization Requests for Arkansas plans during Q4 2020 (10/1/20-12/31/20)

**Q3 2020**

<b>Provider Specialty Type</b>	<b>Drug</b>	<b>Treatment Description</b>	<b>Decision</b>
DERMATOLOGY	Cosentyx Pen (2 pen) 150mg/ml	Psoriatic Arthritis	Approval